XML 70 R57.htm IDEA: XBRL DOCUMENT v3.23.2
FINANCIAL INSTRUMENTS - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2019
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
wholesaler
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
wholesaler
Nov. 30, 2021
USD ($)
Concentration Risk [Line Items]              
Changes in contingent consideration       $ (6,640,000) $ (22,351,000)    
Interest receivable   $ 900,000   $ 900,000   $ 800,000  
Number of major customers | wholesaler       3   3  
Amount of allowance for doubtful accounts   0   $ 0   $ 0  
Accounts Receivable | Concentration Risk By Major Customer | Major Customer One              
Concentration Risk [Line Items]              
Concentration risk (as a percent)       36.00%   34.00%  
Accounts Receivable | Concentration Risk By Major Customer | Major Customer Two              
Concentration Risk [Line Items]              
Concentration risk (as a percent)       21.00%   19.00%  
Accounts Receivable | Concentration Risk By Major Customer | Major Customer Three              
Concentration Risk [Line Items]              
Concentration risk (as a percent)       15.00%   18.00%  
Flexion And MyoScience Acquisition              
Concentration Risk [Line Items]              
Acquisition-related contingent consideration   21,500,000   $ 21,500,000   $ 28,100,000  
Flexion Acquisition              
Concentration Risk [Line Items]              
Acquisition-related contingent consideration   425,500,000   $ 425,500,000     $ 372,300,000
Payment term       60 days      
Changes in contingent consideration   18,300,000 $ 12,500,000 $ 6,600,000 13,300,000    
Contingent consideration   $ 21,500,000   $ 21,500,000   28,100,000  
Flexion Acquisition | Weighted Average | Contingent Consideration | Level 3 | Measurement Input, Discount Rate              
Concentration Risk [Line Items]              
Measurement input, contingent consideration   0.102   0.102      
Flexion Acquisition | Weighted Average | Contingent Consideration | Level 3 | Measurement Input, Probability of Success of Regulatory Milestones              
Concentration Risk [Line Items]              
Measurement input, contingent consideration   0.125   0.125      
Myoscience Acquisition              
Concentration Risk [Line Items]              
Acquisition-related contingent consideration   $ 0   $ 0   $ 0  
Payment term 60 days            
Changes in contingent consideration   0 $ 8,757,000 0 $ 9,034,000    
Contingent consideration $ 100,000,000            
Contingent consideration, current   $ 43,000,000   $ 43,000,000      
Myoscience Acquisition | Contingent Consideration | Level 3 | Measurement Input, Expected Milestone Payment              
Concentration Risk [Line Items]              
Measurement input, contingent consideration   0   0